Objective: To determine whether an association exists between adiponectin and plaque composition in human coronary arteries.
dentification of clinically useful cardiometabolic biomarkers is a priority in cardiovascular medicine to improve the pathophysiologic understanding of metabolic vascular disease and because traditional risk factors neither completely estimate the risk of future sudden cardiac events nor localize this risk to a segment of the coronary artery. In fact, recent consensus guidelines (1) on screening for coronary artery disease in diabetic patients published by the American Diabetes Association expressed a need for clinical studies to characterize plaque composition and stability in combination with the use of biomarkers. Adiponectin is derived from adipose tissue, with low levels associated with obesity, insulin resistance (2), type 2 diabetes (3), risk of non-fatal myocardial infarction (4) , and lipid oxidation (5) . An association with early atherosclerosis has also been suggested (6) .
Intravascular ultrasound (IVUS) provides transmural imaging of the coronary artery wall with reproducible measures of coronary atherosclerosis (7) . IVUS-Virtual Histology (VH) TM categorizes atherosclerotic plaque into 4 distinct components (fibrous, fibrofatty, dense calcium, necrotic core) using autoregressive modeling of radiofrequency data. Currently, the association between adiponectin and atherosclerotic burden and plaque composition is unknown. Therefore, the objectives of this study were to identify an association between adiponectin levels and 1) extent of IVUS-defined coronary atherosclerosis and 2) IVUS-VH plaque composition in human coronary arteries.
RESEARCH DESIGN AND METHODS
Patient Population. Study subjects were enrolled in an IVUS sub-study of the Diabetes Genome Project (DGP) (clinicaltrials.gov #NCT00428961). Briefly, the DGP is a single-center prospective gene and biomarker banking registry designed to collect extensive clinical and anatomic information on coronary angiography patients. All patients consent to provide fasting blood samples. Patients <18 years old with hemoglobin <9 g/dL and undergoing sedation within the past 12 hours are not eligible for enrollment. Patients enrolled in the IVUS sub-study underwent IVUS at the discretion of the operator for the following indications: 1) assessment of an indeterminate lesion; 2) investigation of a culprit lesion for optimal device sizing; 3) post-stent assessment; or 4) clarification of coronary lesion extent. This study was approved by the Saint Luke's Hospital Institutional Review Board. IVUS-VH Image Acquisition and Analysis. Vessels were imaged using IVUS-VH (Volcano Corp., Rancho Cordova, California) (8) (9) (10) (11) (12) . Briefly, IVUS-VH utilizes the mathematical technique of autoregressive modeling to classify the IVUS-radiofrequency data into one of four color-coded plaque components: fibrous (green), fibrofatty (lightgreen), dense calcium (white), and necrotic core (red). IVUS was performed using a 20-MHz catheter (Eagle Eye ® Gold; Volcano). Retrograde imaging was performed using a continuous motorized pullback system at a speed of 0.5 mm/s (R-100 TM . Adiponectin values were non-normally distributed according to the Shapiro-Wilk test (P < 0.0001); therefore a log transformation was used to adhere to normal distribution assumptions (P = 0.9). Pearson productmoment correlation coefficients were calculated to test the correlation between log adiponectin and various markers of interest. Spearman's ρ and Kendall's τ, both nonparametric correlation tests, gave similar results. When comparing adiponectin values across population sub-groups, the Wilcoxon rank-sum test was performed and results reported as median (IQR). Analyses were conducted using SAS Version 9.1 (SAS Institute, Cary, NC).
RESULTS
Characteristics of the study population are presented in Table 1 . On admission, 138 (75%) patients were on lipid lowering therapy, the majority of which were statins (128, 93%). Antihypertensive medications consisted of beta blockers (124, 67%) and renin angiotensin system (RAS) inhibitors (99, 54%). Diabetic patients were more likely to be on a renin-angiotensin system inhibitor compared to non-diabetic patients (65 vs 47%, P = 0.02). Among the 66 diabetic patients, 36 (55%) were treated with oral agents only, 14 (21%) with insulin only, 8 (12%) with oral and insulin therapy, 5 (8%) with no therapy, and 3 (5%) with diet only. Oral diabetic agents consisted of biguanides (n = 27), sulfonylureas (n = 19), thiazolidinediones (n = 6), or combination (n = 7).
The median (IQR) adiponectin level for the study group was 6.1 (2.5, 9.3) µg/mL. Adiponectin levels were significantly lower in males than females (5.
µg/mL, P<0.001). Adiponectin correlated with age (r = 0.3, P < 0.0001), body mass index (r = -0.17, P = 0.02), HOMA (r = -0.17, P = 0.02), and fasting insulin (r = -0.20, P = 0.008). Adiponectin did not correlate with diabetes, hemoglobin A1c, fasting glucose, or albuminuria (data not shown).
Adiponectin levels correlated with atherogenic lipoproteins. Adiponectin correlated with triglycerides (r = -0.27, P = 0.0002) and HDL cholesterol (r = 0.4, P < 0.001). Although there was no significant correlation between adiponectin and total or LDL cholesterol, there were significant associations with the small, dense LDL 3 (r = -0.27, P = 0.003) and LDL 4 (r = -0.25, P = 0.0005) subfractions and the larger, more buoyant LDL 2 (r = 0.18, P = 0.015).
Analyzed (Figure 2a ) volume and percent fibrofatty composition (r = -0.19, P = 0.009). There was also an association with normalized fibrous volume (r = -0.18, P = 0.013) but no association with normalized volume of calcium (r = 0.008, P = 0.9) or necrotic core (r = 0.13, P = 0.13). There were also quantitative differences in fibrofatty content by adiponectin quartiles (Table 2 and Figure 2b ). Normalized volume values for other plaque constituents are shown in Table  2 .
Adiponectin levels were similar in diabetic and non-diabetic patients (5.70 [3.3, 9.1] vs 6.2 [3.6, 10.3] µg/mL, respectively, P = 0.49). In non-diabetic patients, adiponectin correlated with plaque volume (r = -0.22, P = 0.01), fibrofatty volume (r = -0.23, P = 0.01), and percent fibrofatty composition (r = -0.23, P = 0.009); however there were no significant associations in diabetic patients. With increasing adiponectin quartiles, normalized fibrofatty volume decreased in non-diabetic but not diabetic patients (Table 2) 
CONCLUSIONS
The novel findings of this study include a 1) correlation between adiponectin and quantitative IVUS measures of coronary atherosclerosis; 2) correlation between adiponectin and plaque lipid content in IVUS-VH entire pullback analysis; and 3) higher frequency of ID-pathological intimal thickening in patients with lower adiponectin levels. These findings were seen mostly in non-diabetic patients. Our findings are consistent with others (5) regarding the association between adiponectin and atherogenic dylipidemia including elevated triglycerides, low HDL, and small dense LDL cholesterol .
Adiponectin is a unique adipokine, downregulated in the presence of increasing central adiposity and associated with insulin resistance , inflammation , risk for metabolic syndrome , type 2 diabetes (3), decreased LDL particle size , and small dense HDL. Increased levels have also been associated with reduced risk of myocardial infarction even following adjustment for traditional cardiovascular risk factors (4) . However, the association between serum adiponectin and coronary events remains controversial (21) (22) (23) (24) . Prior studies have shown a significant inverse correlation between coronary lumen narrowing as assessed by angiography and plasma adiponectin levels (25; 26). To date, no studies have established a relationship between adiponectin and atherosclerotic burden and plaque composition.
Recent studies indicate that elevated adiponectin levels are associated with adverse outcomes in patients with established coronary atherosclerosis (24; 27-29) . This work suggests a complex relationship between adiponectin and atherosclerosis. While our study does not resolve this issue, it does suggest that low levels of adiponectin are associated with relatively early plaque development and risk of plaque maturation. Consistent with the findings of others that high adiponectin levels are associated with adverse events in patients with advanced atherosclerosis, we found a positive correlation between higher adiponectin levels and the advanced (ID-fibrocalcific) plaque phenotype. However, this apparent paradox can only be resolved by a longitudinal study with serial adiponectin and IVUS measurements and collection of vital statistics.
Classification of lesion morphology (14) has been used in prior histopathology and IVUS studies (15; 30) . Adaptive and pathological intimal thickening are thought to represent early atherosclerosis. Adaptive intimal thickening is characterized by presence of smooth muscle cells and absence of foam cells, thrombus, lipid, and necrotic core. While also absent thrombus and necrotic core, increased lipid accumulation is implicit in the transformation from adaptive to pathological intimal thickening (14; 30) . Although extensively studied, lipid accumulation in the vessel wall is incompletely understood. It is believed that transport of lipoproteins across the endothelial cell monolayer is an initial step in atherogenesis and also likely enhanced in the presence of oxidized LDL. A biological association between adiponectin and atherosclerosis seems plausible. In our study, low adiponectin levels were associated with a higher prevalence of small dense LDL particles. LDL may be indirectly associated with plaque lipid accumulation via oxidizedsmall dense LDL particles. Small dense LDL is associated with endothelial cell injury and increased permeability (31) . Further, adiponectin may play a regulatory role in foam cell maturation. At physiologic concentrations of adiponectin, the expression of class A macrophage scavenger receptor (MSR) is suppressed. Adiponectin also dosedependently decreases class A MSR ligand binding and uptake activities, suggesting a preventive role in foam cell maturation and subsequent atherosclerosis progression (32) .
Despite the novelty of our findings, there are several important limitations. This was an association study and does not establish a causal relationship between adiponectin and lipid accumulation in human atherosclerosis. Our correlation coefficients between adiponectin and lipid volume are modest. Adiponectin accounted for approximately 5-6% of the variability in plaque lipid accumulation, thus other biomarkers may be principally involved in lipid accumulation. It is also conceivable that the association between adiponectin and lipid in plaque was weakened by our use of a non-sensitive adiponectin assay that did not quantify high molecular weight (HMW) multimers (33) . Emerging data suggest the HMW isomer is bioactive (34) . Although we found associations between low adiponectin levels and measures of plaque burden and increased lipid content, the clinical implications of these findings are currently unknown. There are no IVUS-VH data demonstrating lipid-rich plaque as a requisite intermediate step in the progression to advanced plaque phenotypes (thin cap fibroatheroma and fibroatheroma). Another confounding issue for adiponectin levels is the imbalance in use of concomitant medications (6) . RAS blockers and peroxisome proliferator-activated receptor-γ agonists have been shown to increase adiponectin levels. RAS blockers were used in 54% of patients and were more common in diabetic patients. Furthermore approximately 10% of diabetic patients received thiazolidinediones. In a cohort of CAD patients, lower adiponectin levels are associated with small, dense LDL cholesterol, increased plaque volume as measured by lipid-rich atheroma, and a higher prevalence of ID-pathological intimal thickening in non-diabetic patients, suggesting an anti-atherogenic role for adiponectin. 
